WhiteLab Genomics Raises $10 Million in Funding  

by Kay Aloha Villamor September 15th, 2022

WhiteLab Genomics, a France-based Y-Combinator-backed AI-powered predictive software simulation platform for the design of gene and cell therapies, announced a $10 million funding round. 

The round was led by Omnes Capital, one of the leading French venture capital firms, and Debiopharm, a Switzerland-based independent biopharmaceutical company with a venture arm focused on digital health.

WhiteLab Genomics aims to revolutionize genomic therapy development using public and private data and in-house AI algorithms. 

The proceeds from this financing round will help further develop WhiteLab Genomics' AI-based platform, scale its R&D team, and fund its expansion to the US. 

"We are experiencing a strong demand from leading pharmaceutical and biotechnology companies within many sectors of healthcare. They all understand the huge potential of genomic therapies and the significant role of data and AI when it comes to advancing and developing healthcare. At WhiteLab Genomics, we offer our expertise, specific sets of data and algorithms dedicated to their therapies. Now, to best meet our prospects and customers' needs, we need to scale all sectors of our company." said David Del Bourgo, co-founder and CEO of WhiteLab Genomics.

Company: WhiteLab Genomics

Raised: $10.0M

Round: Unknown 

Funding Month: September 2022

Lead Investors: Omnes Capital and Debiopharm

Additional Investors: 

Company Website: https://whitelabgx.com/

Software Category: Gene and Cell Therapies-AI Software solutions

About the Company: Founded in 2019 by David Del Bourgo and Julien Cottineau, experts in genomics drug development and commercialization, WhiteLab Genomics develops state-of-the-art software solutions using AI to accelerate and de-risk gene and cell therapy developments. WhiteLab Genomics currently serves biotech and pharmaceutical companies in Europe and the United States by providing solutions for new drug development programs such as RNA, DNA, and cell-based therapies. WhiteLab Genomics is also collaborating with world-renowned INSERM and Genethon laboratories and has been accepted into Y-Winter Combinator's 2022 batch. WhiteLab Genomics has its headquarters in Paris, France, and is currently establishing its US operations in Cambridge, MA.

Source: https://www.azorobotics.com/News.aspx?newsID=13241


 

 

 

 


Your cart
    Checkout